• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why Pharvaris (PHVS) Is Up 7.3% And What's Next After Phase 3 Trial Success

    Simply Wall St·10/20/2026 05:39:07
    Listen to the news
    • Pharvaris reported that the RAPIDe-3 phase 3 trial of oral deucrictibant immediate release for on demand hereditary angioedema treatment met its primary and 11 secondary endpoints with high statistical significance, showed a well tolerated safety profile, and the results were published in The Lancet.
    • The RAPIDe-3 data support Pharvaris' goal of offering an oral alternative for acute hereditary angioedema attacks across diverse patient subgroups, complementing its extended release prophylaxis program and ongoing regulatory reviews in the US and EU.
    • This article examines how Pharvaris' investment narrative is influenced by RAPIDe-3's phase 3 results and their publication in The Lancet.

    Scan how pharma catalysts like Pharvaris' RAPIDe-3 readout compare with other late-stage opportunities across our hand picked 20 high quality undiscovered gems.

    Pharvaris Investment Narrative Recap

    Owning Pharvaris means believing deucrictibant can become a broad oral franchise across on demand and prophylactic hereditary angioedema care, then potentially wider bradykinin mediated angioedema. The RAPIDe 3 publication in The Lancet reinforces that core thesis operationally, because it strengthens the clinical package behind the on demand capsule already under FDA and EMA review.

    The most important near term catalyst still looks like the April 23, 2027 PDUFA decision on deucrictibant IR, with the prophylaxis filing timeline a close second. The big risk remains unchanged. Pharvaris is pre revenue, loss making at €39.2 million in Q1 2026, and dependent on regulatory progress plus future capital access.

    The RAPIDe 3 data publication is tightly linked to Pharvaris' NDA and MAA under review for deucrictibant IR. A positive, well tolerated phase 3 dataset in a high impact journal can matter for payer discussions, physician education, and guideline adoption once regulators reach their decisions, especially for a first oral option in a niche disease.

    For catalysts, this announcement pairs with the ongoing RAPIDe 2 extension and expanded access program in the U.S., which keep real world experience building while the business has no commercial revenue. That operational progress sits against meaningful risks, including continued cash burn, potential future dilution, and any change in regulatory timelines for both IR and XR formulations.

    Pharvaris consensus expectations after RAPIDe-3

    Pharvaris' investment story after RAPIDe 3 is built on the shift from a research heavy rare disease biotech with no product revenue today to a business analysts expect to be generating material hereditary angioedema sales by the late 2020s. The clinical readout and Lancet publication help frame how much change is already reflected in current models, because forecasts now tie scientific progress directly to specific revenue, earnings and valuation hurdles.

    Analysts currently model Pharvaris moving from zero revenue to €317.3 million by 2029, with earnings moving from a loss of €170.9 million today to a profit of €32.4 million. That swing in profitability implies an earnings change of about €203 million over the forecast window. On those estimates, the stock would be trading on a P/E multiple of 167x in 2029 compared with a current P/E of 11.5x based on the loss profile, which is above the 15.3x sector level cited in the report.

    Pharvaris' narrative projects €317.3 million revenue and €32.4 million earnings by 2029. This implies yearly revenue growth from zero to the forecast level and an earnings increase of about €203 million from a loss of €170.9 million today to the projected €32.4 million profit.

    Uncover how Pharvaris' fair value indicates a 93% potential upside to its current price before the market closes the gap.

    NasdaqGS:PHVS 1-Year Stock Price Chart
    NasdaqGS:PHVS 1-Year Stock Price Chart

    Exploring Other Perspectives

    For Pharvaris, the sharpest contrast is uptake risk. The most cautious analysts were only pencilling in about €203.1 million of revenue and roughly €34.7 million of earnings by 2029, far below consensus, because they feared slow adoption despite solid data. Those views were set before this RAPIDe-3 news, so opinions may evolve and it is worth exploring several angles yourself.

    Explore 2 other Pharvaris fair value estimates, including one that suggests it could be worth just $57.33!

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider conducting your own research and forming your own view.

    Looking for more investment ideas beyond Pharvaris?

    Once you have formed a view on Pharvaris, it can help to widen the lens and compare it with other potential opportunities using the Simply Wall St Screener.